Health Policy Associates, Inc. (HPA) is a highly experienced, U.S.-based full-service CRO specializing in the design, execution, and oversight of clinical trials for biologic medical products.
With more than 20 years of CRO experience and decades of regulatory interaction with the U.S. FDA, HPA delivers efficient, high-quality clinical trials for innovative biologics across a broad range of therapeutic areas.
HPA supports Phase I through Phase III clinical trials for a broad range of biologic products, including cell-based and tissue-based therapies, regenerative medicine technologies, orthobiologics, injectable and implantable biologics, combination products, and other novel therapeutic platforms. Our team brings deep experience guiding innovative biologic technologies from early clinical development through pivotal studies.
